Gastrointestinal Devices Market by Product Type (Capsule Endoscopy Systems, Endoscopic Imaging Systems, Endotherapy Devices), Technology (Capsule Endoscopy, Optical Endoscopy, Robotic Endoscopy), Application, End User - Global Forecast 2025-2032
Description
The Gastrointestinal Devices Market was valued at USD 8.11 billion in 2024 and is projected to grow to USD 8.76 billion in 2025, with a CAGR of 7.90%, reaching USD 14.91 billion by 2032.
A concise orientation to the converging clinical, technological, and operational drivers reshaping gastrointestinal device development and provider adoption
The gastrointestinal devices landscape stands at a pivotal intersection of clinical demand, technological innovation, and evolving regulatory expectations. This introduction frames the current environment by outlining the converging trends that shape device development and deployment. Advances in imaging fidelity, minimally invasive platform design, and integrated hemostasis techniques are complemented by heightened clinician emphasis on procedural efficiency and patient safety. As a result, stakeholders across the value chain must recalibrate clinical pathways, procurement criteria, and R&D priorities to align with the imperatives of diagnostic accuracy and therapeutic efficacy.
Moreover, the introduction situates these technical shifts within the broader operational realities that providers face. Supply chain resilience, device interoperability, and training requirements increasingly influence adoption curves. Consequently, industry participants must adopt a systems-level perspective that accounts for hospital workflow integration, cross-disciplinary collaboration, and lifecycle support. Taken together, these forces create both opportunity and responsibility for manufacturers, providers, and investors seeking to deliver measurable improvements in outcomes and procedural throughput.
How advancements in visualization, miniaturization, and care delivery models are driving fundamental transformations across gastrointestinal device design and clinical adoption
The landscape for gastrointestinal devices is undergoing transformative shifts driven by technological maturation, changing clinical expectations, and new models of care delivery. High-definition visualization and digital image processing have elevated lesion detection capabilities while enabling more consistent documentation and remote consultation workflows. At the same time, miniaturization and robotic assistance are expanding the therapeutic reach of endoscopic platforms, permitting interventions in anatomically challenging regions and reducing patient recovery times. Consequently, research and development pipelines are prioritizing modular architectures and software-enabled diagnostics that can evolve with iterative clinical validation.
Concurrently, care delivery models are shifting toward ambulatory and outpatient settings, which emphasize procedure throughput, cost containment, and patient experience. This transition spurs demand for devices that balance robustness with ease of use, lower capital intensity, and streamlined reprocessing protocols. In parallel, regulatory focus on safety and post-market surveillance is increasing, prompting more rigorous preclinical testing and lifecycle data collection. Together, these changes encourage manufacturers to invest in integrated solutions that combine superior imaging, targeted endotherapy, and workflow intelligence to meet the dual objectives of clinician empowerment and operational efficiency.
Assessing the strategic ripple effects of United States tariff adjustments in 2025 on supply chains, sourcing strategies, and commercial resilience in gastrointestinal devices
The imposition and adjustment of tariffs in the United States during 2025 have created a multifaceted impact on gastrointestinal device supply chains, procurement strategies, and competitive positioning. Tariff changes increased scrutiny of cross-border sourcing decisions and accelerated strategic initiatives to localize critical manufacturing steps. As a result, procurement teams re-evaluated supplier contracts and sought dual-sourcing arrangements to mitigate exposure to additional duties. This, in turn, affected pricing negotiations and extended lead-time planning, especially for capital-intense imaging platforms and specialized endotherapy consumables that rely on tightly integrated global suppliers.
Beyond procurement, the tariff environment influenced investment choices and operational risk assessments. Manufacturers and contract manufacturers responded by reconfiguring supply footprints, qualifying regional suppliers, and optimizing bill-of-materials to reduce tariffable content. At the same time, tariffs prompted greater emphasis on regulatory harmonization and tariff classification accuracy to avoid unintended duty liabilities. Consequently, organizations that proactively established more localized manufacturing capabilities, secured diversified supplier bases, and adapted commercial terms gained relative resilience. Moving forward, stakeholders should expect that trade policy volatility will remain a factor in strategic planning, requiring dynamic sourcing playbooks and stronger scenario planning to preserve continuity of care and innovation velocity.
In-depth segmentation perspective demonstrating how product types, clinical applications, end-user environments, and enabling technologies intersect to shape strategic priorities
Segmentation analysis reveals the nuanced dynamics that govern product development priorities and buyer preferences across the gastrointestinal device landscape. Based on product type, the market spans capsule endoscopy systems, endoscopic imaging systems, endotherapy devices, and hemostasis devices. Within endoscopic imaging systems, high-definition endoscopes, ultrathin endoscopes, and video endoscopes each address distinct clinical use cases and clinician ergonomics. Endotherapy devices encompass dilation balloons, polypectomy devices, and stents, which vary by therapeutic intent and reintervention risk. Hemostasis devices include clips, hemostatic powders, and thermal coagulation devices, each offering trade-offs in immediacy of effect, ease of deployment, and compatibility with concurrent therapies.
When segmented by application, the landscape covers bleeding management, diagnostic imaging, polyp detection, and stricture dilation. Bleeding management further differentiates into mechanical hemostasis, sprayable hemostats, and thermal coagulation approaches, while diagnostic imaging bifurcates into lesion visualization and motility assessment. This application focus informs device feature prioritization and clinical training needs. By end user, the market serves ambulatory surgical centers, diagnostic centers, hospitals, and specialty clinics, each of which imposes different capital, procedural throughput, and sterilization constraints. Finally, by technology, the spectrum includes capsule endoscopy, optical endoscopy, robotic endoscopy, and ultrasound endoscopy. Optical endoscopy divides into flexible and rigid endoscopes, and ultrasound endoscopy separates into linear and radial ultrasound endoscopes. Understanding these intersecting segments enables stakeholders to align product roadmaps with specific clinical workflows and procurement criteria.
How diverse regional regulatory, reimbursement, and clinical practice environments in the Americas, Europe Middle East & Africa, and Asia-Pacific shape commercialization and adoption strategies
Regional dynamics exert a powerful influence on adoption patterns, regulatory expectations, and investment priorities across the gastrointestinal device sector. In the Americas, providers emphasize integrated platforms that support high procedural volumes and robust post-market evidence, while reimbursement pathways and hospital consolidation shape purchasing cycles. Consequently, manufacturers pursuing traction in this region align clinical evidence generation and service models to support large health systems and ambulatory care networks. In contrast, Europe, Middle East & Africa presents a heterogeneous regulatory and reimbursement landscape where national frameworks alter time-to-market and demand localization of training and support services. Here, interoperability with existing hospital information systems and adherence to diverse clinical guidelines become decisive factors in adoption.
Meanwhile, Asia-Pacific exhibits accelerated uptake of minimally invasive diagnostic and therapeutic modalities driven by rapidly growing healthcare infrastructure and a strong demand for outpatient services. Regional manufacturers and service providers often prioritize cost-effective designs and scalable training programs to capture high-volume opportunities. Across all regions, strategic considerations include regulatory harmonization, supply chain localization, and partnerships with local distributors and clinical networks. These regional nuances require tailored commercialization strategies that adapt product features, evidence generation plans, and service delivery models to local clinical practice and procurement realities.
Competitive and collaborative dynamics illustrating how incumbents, innovative entrants, and strategic partnerships determine pathways to product validation and scaled adoption
Competitive dynamics in the gastrointestinal devices sector reflect a balance between established original equipment manufacturers, innovative startups, and specialized component suppliers. Legacy firms continue to leverage installed base relationships, service networks, and validated clinical evidence, while newer entrants capitalize on software-enabled diagnostics, novel imaging sensors, and single-use consumables to address unmet clinical needs. Investment flows increasingly favor firms that can demonstrate clear clinical differentiation alongside pragmatic deployment models, such as devices that simplify workflows or reduce total procedure time. As a consequence, strategic partnerships between device developers and health systems or academic centers have become a primary mechanism to accelerate evidence generation and refine product-market fit.
In addition, contract manufacturers and tiered supply partners play a strategic role in accelerating time-to-market, particularly for high-complexity imaging modules and precision-engineered endotherapy instruments. The industry also sees selective consolidation where acquirers seek to fill portfolio gaps, expand geographic reach, or internalize technology capabilities. For companies of all sizes, success hinges on aligning product development with clinician needs, maintaining disciplined regulatory pathways, and investing in scalable post-market support structures that reinforce long-term adoption.
Practical and prioritized strategies that device developers and providers can implement to accelerate adoption, reduce risk exposure, and demonstrate measurable clinical value
Industry leaders should adopt a proactive, integrated approach to capture clinical value and operational efficiencies across the gastrointestinal device lifecycle. First, prioritize modular platform designs that permit incremental upgrades in imaging and therapeutic capability, thereby protecting installed base investments and enabling faster regulatory updates. Second, invest in robust clinical evidence programs that link device performance to patient-centric outcomes and operational metrics such as procedure time and reintervention rates. These data-driven narratives strengthen value propositions with payers and health systems and reduce barriers to adoption.
Furthermore, build resilient supply chain architectures by qualifying regional manufacturing partners, optimizing the bill-of-materials to lower tariff exposure, and establishing rapid-response inventory strategies. Leaders should also cultivate strategic alliances with hospital networks, academic centers, and technology partners to co-develop training curricula and digital workflow integrations. Finally, commit to post-market surveillance and lifecycle support models that demonstrate long-term safety and cost-effectiveness; such commitments enhance trust with clinicians and procurement teams and create defensible competitive differentiation in crowded product categories.
Transparent hybrid research methodology combining expert qualitative engagement and systematic secondary evidence synthesis to underpin actionable market insights
This analysis relied on a hybrid research methodology combining primary qualitative engagement with domain experts and systematic secondary evidence review to ensure balanced, actionable insights. Primary research included structured interviews with clinicians, procurement specialists, and device engineers to surface real-world workflow constraints, clinician preferences, and manufacturing considerations. These conversations informed the framing of technical trade-offs and adoption drivers and provided context for regional and end-user specific dynamics. In parallel, secondary research reviewed peer-reviewed clinical literature, regulatory guidance documents, and technical white papers to validate device performance characteristics and safety considerations.
Data synthesis employed triangulation techniques to reconcile divergent viewpoints and to identify consensus trends. Quality controls included cross-validation of interview findings, independent review by clinical advisors, and reproducibility checks on methodological assumptions. Limitations are acknowledged: qualitative inputs may reflect institutional practices that do not universally apply, and evolving regulatory or trade developments could shift strategic priorities. Nevertheless, the methodology emphasizes transparency, reproducibility, and relevance to commercial decision-making by combining practitioner insights with rigorous document review.
Synthesis of strategic imperatives and forward-looking considerations that align innovation, evidence generation, and operational resilience to accelerate meaningful clinical impact
In conclusion, the gastrointestinal devices landscape is characterized by rapid technological advancement, shifting care pathways, and evolving commercial pressures that collectively redefine opportunity and risk. High-resolution imaging, robotics, and focused endotherapy capabilities are converging to expand what is clinically feasible in minimally invasive care. At the same time, supply chain disruptions and trade policy shifts underscore the need for resilient sourcing and flexible manufacturing strategies. Stakeholders that integrate clinical evidence, operational pragmatism, and strategic partnerships will be best positioned to translate technological promise into measurable improvements in patient care and system efficiency.
Looking ahead, success will depend on an ability to adapt product architectures to diverse clinical environments, to demonstrate value through rigorous evidence, and to maintain responsive commercial and manufacturing models that accommodate regional nuances. By aligning innovation with pragmatic deployment and lifecycle support, manufacturers and providers can accelerate adoption while managing financial and operational risk, thereby delivering tangible benefits to clinicians and patients alike.
Note: PDF & Excel + Online Access - 1 Year
A concise orientation to the converging clinical, technological, and operational drivers reshaping gastrointestinal device development and provider adoption
The gastrointestinal devices landscape stands at a pivotal intersection of clinical demand, technological innovation, and evolving regulatory expectations. This introduction frames the current environment by outlining the converging trends that shape device development and deployment. Advances in imaging fidelity, minimally invasive platform design, and integrated hemostasis techniques are complemented by heightened clinician emphasis on procedural efficiency and patient safety. As a result, stakeholders across the value chain must recalibrate clinical pathways, procurement criteria, and R&D priorities to align with the imperatives of diagnostic accuracy and therapeutic efficacy.
Moreover, the introduction situates these technical shifts within the broader operational realities that providers face. Supply chain resilience, device interoperability, and training requirements increasingly influence adoption curves. Consequently, industry participants must adopt a systems-level perspective that accounts for hospital workflow integration, cross-disciplinary collaboration, and lifecycle support. Taken together, these forces create both opportunity and responsibility for manufacturers, providers, and investors seeking to deliver measurable improvements in outcomes and procedural throughput.
How advancements in visualization, miniaturization, and care delivery models are driving fundamental transformations across gastrointestinal device design and clinical adoption
The landscape for gastrointestinal devices is undergoing transformative shifts driven by technological maturation, changing clinical expectations, and new models of care delivery. High-definition visualization and digital image processing have elevated lesion detection capabilities while enabling more consistent documentation and remote consultation workflows. At the same time, miniaturization and robotic assistance are expanding the therapeutic reach of endoscopic platforms, permitting interventions in anatomically challenging regions and reducing patient recovery times. Consequently, research and development pipelines are prioritizing modular architectures and software-enabled diagnostics that can evolve with iterative clinical validation.
Concurrently, care delivery models are shifting toward ambulatory and outpatient settings, which emphasize procedure throughput, cost containment, and patient experience. This transition spurs demand for devices that balance robustness with ease of use, lower capital intensity, and streamlined reprocessing protocols. In parallel, regulatory focus on safety and post-market surveillance is increasing, prompting more rigorous preclinical testing and lifecycle data collection. Together, these changes encourage manufacturers to invest in integrated solutions that combine superior imaging, targeted endotherapy, and workflow intelligence to meet the dual objectives of clinician empowerment and operational efficiency.
Assessing the strategic ripple effects of United States tariff adjustments in 2025 on supply chains, sourcing strategies, and commercial resilience in gastrointestinal devices
The imposition and adjustment of tariffs in the United States during 2025 have created a multifaceted impact on gastrointestinal device supply chains, procurement strategies, and competitive positioning. Tariff changes increased scrutiny of cross-border sourcing decisions and accelerated strategic initiatives to localize critical manufacturing steps. As a result, procurement teams re-evaluated supplier contracts and sought dual-sourcing arrangements to mitigate exposure to additional duties. This, in turn, affected pricing negotiations and extended lead-time planning, especially for capital-intense imaging platforms and specialized endotherapy consumables that rely on tightly integrated global suppliers.
Beyond procurement, the tariff environment influenced investment choices and operational risk assessments. Manufacturers and contract manufacturers responded by reconfiguring supply footprints, qualifying regional suppliers, and optimizing bill-of-materials to reduce tariffable content. At the same time, tariffs prompted greater emphasis on regulatory harmonization and tariff classification accuracy to avoid unintended duty liabilities. Consequently, organizations that proactively established more localized manufacturing capabilities, secured diversified supplier bases, and adapted commercial terms gained relative resilience. Moving forward, stakeholders should expect that trade policy volatility will remain a factor in strategic planning, requiring dynamic sourcing playbooks and stronger scenario planning to preserve continuity of care and innovation velocity.
In-depth segmentation perspective demonstrating how product types, clinical applications, end-user environments, and enabling technologies intersect to shape strategic priorities
Segmentation analysis reveals the nuanced dynamics that govern product development priorities and buyer preferences across the gastrointestinal device landscape. Based on product type, the market spans capsule endoscopy systems, endoscopic imaging systems, endotherapy devices, and hemostasis devices. Within endoscopic imaging systems, high-definition endoscopes, ultrathin endoscopes, and video endoscopes each address distinct clinical use cases and clinician ergonomics. Endotherapy devices encompass dilation balloons, polypectomy devices, and stents, which vary by therapeutic intent and reintervention risk. Hemostasis devices include clips, hemostatic powders, and thermal coagulation devices, each offering trade-offs in immediacy of effect, ease of deployment, and compatibility with concurrent therapies.
When segmented by application, the landscape covers bleeding management, diagnostic imaging, polyp detection, and stricture dilation. Bleeding management further differentiates into mechanical hemostasis, sprayable hemostats, and thermal coagulation approaches, while diagnostic imaging bifurcates into lesion visualization and motility assessment. This application focus informs device feature prioritization and clinical training needs. By end user, the market serves ambulatory surgical centers, diagnostic centers, hospitals, and specialty clinics, each of which imposes different capital, procedural throughput, and sterilization constraints. Finally, by technology, the spectrum includes capsule endoscopy, optical endoscopy, robotic endoscopy, and ultrasound endoscopy. Optical endoscopy divides into flexible and rigid endoscopes, and ultrasound endoscopy separates into linear and radial ultrasound endoscopes. Understanding these intersecting segments enables stakeholders to align product roadmaps with specific clinical workflows and procurement criteria.
How diverse regional regulatory, reimbursement, and clinical practice environments in the Americas, Europe Middle East & Africa, and Asia-Pacific shape commercialization and adoption strategies
Regional dynamics exert a powerful influence on adoption patterns, regulatory expectations, and investment priorities across the gastrointestinal device sector. In the Americas, providers emphasize integrated platforms that support high procedural volumes and robust post-market evidence, while reimbursement pathways and hospital consolidation shape purchasing cycles. Consequently, manufacturers pursuing traction in this region align clinical evidence generation and service models to support large health systems and ambulatory care networks. In contrast, Europe, Middle East & Africa presents a heterogeneous regulatory and reimbursement landscape where national frameworks alter time-to-market and demand localization of training and support services. Here, interoperability with existing hospital information systems and adherence to diverse clinical guidelines become decisive factors in adoption.
Meanwhile, Asia-Pacific exhibits accelerated uptake of minimally invasive diagnostic and therapeutic modalities driven by rapidly growing healthcare infrastructure and a strong demand for outpatient services. Regional manufacturers and service providers often prioritize cost-effective designs and scalable training programs to capture high-volume opportunities. Across all regions, strategic considerations include regulatory harmonization, supply chain localization, and partnerships with local distributors and clinical networks. These regional nuances require tailored commercialization strategies that adapt product features, evidence generation plans, and service delivery models to local clinical practice and procurement realities.
Competitive and collaborative dynamics illustrating how incumbents, innovative entrants, and strategic partnerships determine pathways to product validation and scaled adoption
Competitive dynamics in the gastrointestinal devices sector reflect a balance between established original equipment manufacturers, innovative startups, and specialized component suppliers. Legacy firms continue to leverage installed base relationships, service networks, and validated clinical evidence, while newer entrants capitalize on software-enabled diagnostics, novel imaging sensors, and single-use consumables to address unmet clinical needs. Investment flows increasingly favor firms that can demonstrate clear clinical differentiation alongside pragmatic deployment models, such as devices that simplify workflows or reduce total procedure time. As a consequence, strategic partnerships between device developers and health systems or academic centers have become a primary mechanism to accelerate evidence generation and refine product-market fit.
In addition, contract manufacturers and tiered supply partners play a strategic role in accelerating time-to-market, particularly for high-complexity imaging modules and precision-engineered endotherapy instruments. The industry also sees selective consolidation where acquirers seek to fill portfolio gaps, expand geographic reach, or internalize technology capabilities. For companies of all sizes, success hinges on aligning product development with clinician needs, maintaining disciplined regulatory pathways, and investing in scalable post-market support structures that reinforce long-term adoption.
Practical and prioritized strategies that device developers and providers can implement to accelerate adoption, reduce risk exposure, and demonstrate measurable clinical value
Industry leaders should adopt a proactive, integrated approach to capture clinical value and operational efficiencies across the gastrointestinal device lifecycle. First, prioritize modular platform designs that permit incremental upgrades in imaging and therapeutic capability, thereby protecting installed base investments and enabling faster regulatory updates. Second, invest in robust clinical evidence programs that link device performance to patient-centric outcomes and operational metrics such as procedure time and reintervention rates. These data-driven narratives strengthen value propositions with payers and health systems and reduce barriers to adoption.
Furthermore, build resilient supply chain architectures by qualifying regional manufacturing partners, optimizing the bill-of-materials to lower tariff exposure, and establishing rapid-response inventory strategies. Leaders should also cultivate strategic alliances with hospital networks, academic centers, and technology partners to co-develop training curricula and digital workflow integrations. Finally, commit to post-market surveillance and lifecycle support models that demonstrate long-term safety and cost-effectiveness; such commitments enhance trust with clinicians and procurement teams and create defensible competitive differentiation in crowded product categories.
Transparent hybrid research methodology combining expert qualitative engagement and systematic secondary evidence synthesis to underpin actionable market insights
This analysis relied on a hybrid research methodology combining primary qualitative engagement with domain experts and systematic secondary evidence review to ensure balanced, actionable insights. Primary research included structured interviews with clinicians, procurement specialists, and device engineers to surface real-world workflow constraints, clinician preferences, and manufacturing considerations. These conversations informed the framing of technical trade-offs and adoption drivers and provided context for regional and end-user specific dynamics. In parallel, secondary research reviewed peer-reviewed clinical literature, regulatory guidance documents, and technical white papers to validate device performance characteristics and safety considerations.
Data synthesis employed triangulation techniques to reconcile divergent viewpoints and to identify consensus trends. Quality controls included cross-validation of interview findings, independent review by clinical advisors, and reproducibility checks on methodological assumptions. Limitations are acknowledged: qualitative inputs may reflect institutional practices that do not universally apply, and evolving regulatory or trade developments could shift strategic priorities. Nevertheless, the methodology emphasizes transparency, reproducibility, and relevance to commercial decision-making by combining practitioner insights with rigorous document review.
Synthesis of strategic imperatives and forward-looking considerations that align innovation, evidence generation, and operational resilience to accelerate meaningful clinical impact
In conclusion, the gastrointestinal devices landscape is characterized by rapid technological advancement, shifting care pathways, and evolving commercial pressures that collectively redefine opportunity and risk. High-resolution imaging, robotics, and focused endotherapy capabilities are converging to expand what is clinically feasible in minimally invasive care. At the same time, supply chain disruptions and trade policy shifts underscore the need for resilient sourcing and flexible manufacturing strategies. Stakeholders that integrate clinical evidence, operational pragmatism, and strategic partnerships will be best positioned to translate technological promise into measurable improvements in patient care and system efficiency.
Looking ahead, success will depend on an ability to adapt product architectures to diverse clinical environments, to demonstrate value through rigorous evidence, and to maintain responsive commercial and manufacturing models that accommodate regional nuances. By aligning innovation with pragmatic deployment and lifecycle support, manufacturers and providers can accelerate adoption while managing financial and operational risk, thereby delivering tangible benefits to clinicians and patients alike.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
198 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Development of AI-powered capsule endoscopy systems for early gastrointestinal disease detection
- 5.2. Expansion of minimally invasive robotic-assisted endoluminal procedures in GI treatments
- 5.3. Integration of real-time remote monitoring sensors in smart gastrointestinal stents and catheters
- 5.4. Emerging adoption of biodegradable polymer-based esophageal and colonic stents to reduce complications
- 5.5. Advances in automated precision drug delivery systems for targeted gastrointestinal therapy
- 5.6. Growth of disposable single-use endoscopes to enhance procedure safety and reduce cross-contamination
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Gastrointestinal Devices Market, by Product Type
- 8.1. Capsule Endoscopy Systems
- 8.2. Endoscopic Imaging Systems
- 8.2.1. High Definition Endoscopes
- 8.2.2. Ultrathin Endoscopes
- 8.2.3. Video Endoscopes
- 8.3. Endotherapy Devices
- 8.3.1. Dilation Balloons
- 8.3.2. Polypectomy Devices
- 8.3.3. Stents
- 8.4. Hemostasis Devices
- 8.4.1. Clips
- 8.4.2. Hemostatic Powders
- 8.4.3. Thermal Coagulation Devices
- 9. Gastrointestinal Devices Market, by Technology
- 9.1. Capsule Endoscopy
- 9.2. Optical Endoscopy
- 9.2.1. Flexible Endoscopes
- 9.2.2. Rigid Endoscopes
- 9.3. Robotic Endoscopy
- 9.4. Ultrasound Endoscopy
- 9.4.1. Linear Ultrasound Endoscopes
- 9.4.2. Radial Ultrasound Endoscopes
- 10. Gastrointestinal Devices Market, by Application
- 10.1. Bleeding Management
- 10.1.1. Mechanical Hemostasis
- 10.1.2. Sprayable Hemostats
- 10.1.3. Thermal Coagulation
- 10.2. Diagnostic Imaging
- 10.2.1. Lesion Visualization
- 10.2.2. Motility Assessment
- 10.3. Polyp Detection
- 10.4. Stricture Dilation
- 11. Gastrointestinal Devices Market, by End User
- 11.1. Ambulatory Surgical Centers
- 11.2. Diagnostic Centers
- 11.3. Hospitals
- 11.4. Specialty Clinics
- 12. Gastrointestinal Devices Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Gastrointestinal Devices Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Gastrointestinal Devices Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Medtronic plc
- 15.3.2. Boston Scientific Corporation
- 15.3.3. Johnson & Johnson Services, Inc.
- 15.3.4. Olympus Corporation
- 15.3.5. Becton, Dickinson and Company
- 15.3.6. Fujifilm Holdings Corporation
- 15.3.7. Pentax Medical by HOYA Corporation
- 15.3.8. STERIS Corporation
- 15.3.9. Cook Group Incorporated
- 15.3.10. CONMED Corporation
- 15.3.11. Abbott Laboratories
- 15.3.12. Karl Storz SE & Co. KG
- 15.3.13. Richard Wolf GmbH
- 15.3.14. Smith+Nephew
- 15.3.15. Stryker Corporation
- 15.3.16. Getinge AB
- 15.3.17. Siemens Healthineers AG
- 15.3.18. Micro-Tech (Nanjing) Co., Ltd.
- 15.3.19. Merit Medical Systems, Inc.
- 15.3.20. Ovesco Endoscopy AG
- 15.3.21. Teleflex Incorporated
- 15.3.22. W. L. Gore & Associates, Inc.
- 15.3.23. Prion Medical BV
- 15.3.24. Asahi Kasei Medical Co., Ltd.
- 15.3.25. Leo Medical Co.,Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
